Official Title
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Brief Title
Genomic Study of Relapse Esophageal Cancer After Radiotherapy
Protocol ID
NCT04694391
Lead Sponsor
Fudan University
Brief Summary
Radiotherapy plays an important role in multidisciplinary treatment of esophageal cancer.
However, about half patients received radiotherapy occurred relapse. Once relapse
occurred, there is no better treatment strategy. Genomic study of relapsed esophageal
cancer is seldom. So the investigators attempt to collect relapsed tissue to conduct with
whole exome sequencing in order to investigate the genome landscape of recurrence
esophageal cancer.
Detailed Description
Tumor tissue of patients received radiotherapy with diagnosis of recurrence between Jan
1, 2010 and Dec 1, 2020 were collected retrospectively. Recurrence tumor tissue is
collected between Dec 31, 2020 and Dec 31, 2022 prospectively. Blood and preradiotherapy
tumor tissue were also collected to be as contrast. A total of 100 paired blood,
preradiotherapy tumor tissue and relapse tumor tissue were collected. What is more, a
total of 100 paired blood and preradiotherapy tumor tissue with diagnosis of no
recurrence were collected. All samples were conducted with whole exome sequencing.
Here the investigators define recurrence period as within 2 years and no recurrence
period as more than 3 years after radiotherapy.
Criteria of relapse: (1) pathologic diagnosis is squamous carcinoma before
radiotherapy;(2) received radiotherapy; (3)pathologic diagnosis is also squamous
carcinoma after radiotherapy; (4) clinical symptoms including feeding obstruction etc;
(5) imaging evidence showed disease progression.
Study Period
-
Enrollment Count
200 participants
Eligibility Criteria
Inclusion Criteria:
1. pathologic diagnosis is squamous cell carcinoma before radiotherapy;
2. pathologic diagnosis is squamous cell carcinoma after radiotherapy;
3. received radiotherapy
4. clinical symptoms including dysphagia, feeding obstruction, etc
5. image evidence showed disease progression
6. the period of recurrence was within 2 years after radiotherapy
Exclusion Criteria:
1. pathologic diagnosis is not squamous cell carcinoma before radiotherapy;
2. pathologic diagnosis is not squamous cell carcinoma after radiotherapy
3. not received radiotherapy
4. the period of recurrence was more than 2 years after radiotherapy
5. the period of no recurrence was within 3 years after radiotherapy
Filters
Gene Mutation-Related Cancer
Esophageal Cancer
Radiation Exposure
UNKNOWN
CHILD
ADULT
OLDER_ADULT